AstraZeneca moves team into Cancer Research Cambridge labs
Pharma giant AstraZeneca has entered into a collaboration with the Cancer Research UK (CRUK) Cambridge Institute to temporarily locate up to 60 AZ scientists in the Institute.
It is felt the move will accelerate medical technology innovation – with a particular emphasis on finding breakthrough treatments for cancer.
The CRUK Cambridge Institute, part of the University of Cambridge, is located on the Cambridge Biomedical Campus – the future site of AstraZeneca’s UK-based global strategic research and development centre and corporate headquarters.
AstraZeneca researchers will work alongside counterparts at the CRUK Cambridge Institute’s state-of-the-art laboratories for up to three years.
The move will help to accelerate the integration of the company’s scientists into the Cambridge scientific community ahead of the anticipated opening of the new headquarters in 2016.
The co-location of researchers will also support the existing projects between AstraZeneca, the CRUK Cambridge Institute and other organisations including the University of Cambridge Department of Oncology, the MRC Cancer Unit and Addenbrooke’s Hospital on a number of clinical and pre-clinical oncology projects.
Susan Galbraith, head of AstraZeneca’s Oncology Innovative Medicines Unit said: “We’re thrilled with this early opportunity to join the vibrant Cambridge biomedical community. This will enable AstraZeneca and CRUK Cambridge Institute scientists to work side-by-side, sharing their respective world-class oncology expertise and building on the momentum of our existing research in this vital area.”
Professor Simon Tavaré, Director of the CRUK Cambridge Institute, welcomed the opportunity for further connections with AstraZeneca. “The CRUK Cambridge Institute is keen to develop new research directions with pharma and biotech,” he noted.
Oncology is one of three core therapeutic areas for AstraZeneca and the CRUK Cambridge Institute, part of the Cambridge Cancer Centre, is the largest single facility conducting cancer research in the University of Cambridge.
Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development at AstraZeneca said: “In choosing to locate one of our three global R & D centres at the Cambridge Biomedical Campus we have made a clear statement of intent about putting science at the heart of everything we do.
“That’s why this early collaboration with the CRUK Cambridge Institute is so exciting, as it represents another step in our efforts to create a permeable research infrastructure, building strong relationships with the vibrant bioscience community in the city as we work on developing the innovative medicines of the future.”
• PHOTOGRAPH SHOWS: Susan Galbraith of AstraZeneca addressing delegates at the ON Helix conference at the Wellcome Trust Genome Campus on July 9, 2013